EyeBio Raise $65M in Series A Funding for the Development of a New Generation of Eye Disease Therapies.
EyeBio have announced their successful $65M Series A funding to develop new generation of eye disease therapies. Their aim is to ‘protect, restore and improve vision’ of patients, they will use this funding to assemble and develop a ‘diversified pipeline of product candidates’ that combines scientific targets with innovative translational approaches.
“Advances in research are revealing new opportunities to translate science into solutions that serve patients with eye diseases who have urgent and unaddressed medical needs” Dr David Guyer, CEO EyeBio.
The Series A funding will bring together an international team of executives and investors with a track record for developing #ophthalmology therapies.
Follow Vision Executives to stay up to date with the latest #eyecare news and vacancies.
Last year, we wrote an article on the use of Gene Therapy in ophthalmology which was published in The Ophthalmologist (link in comments). One company we featured was ProQR Therapeutics who are developing RNA therapies for inherited retinal diseases. ProQR recently announced their TopLine Phase 2/3 results from their lead program (Sepofarsen) which unfortunately came back with some disappointing results.
The ‘study did not meet primary endpoint nor notable secondary endpoints’. “Given the results observed in earlier studies of sepofarsen, the Illuminate trial results are unexpected and disappointing, especially for people living with LCA10” Daniel A. de Boer, Founder and CEO of ProQR Therapeutics.
Although this is disappointing news, what they and the other companies we included in our Gene Therapy article are attempting to do is to cure blindness for certain diseases. This has always been a huge challenge and companies shouldn’t be discouraged by negative clinical trail results as they usually have multiple programmes that they can apply their new findings to.
The only way we can make progress on these awful diseases is by trying our best and failing, but we should learn from what hasn’t worked.
Vision Executives are delighted to announce the upcoming launch our our EYE-INTRO recruitment platform which will take our candidate and client services to the next level. As we roll this out in the next few months our retained clients will get exclusive access to what we believe is the future of recruitment.
No more losing candidates information in email chains and no more back and forth to arrange interviews.
Our new platform includes:
✅Campaign management (all of your candidates in one place)
✅Employer branding for campaigns (improve brand awareness)
✅Candidate location map (the right people in the right places)
✅Candidate participation (intro videos)
✅Competency questionnaires (to assess skills)
✅Behavioural assessments (to assess cultural fit)
✅Executive summary (our feedback on candidates suitability)
✅Interview scheduler (aligns your calendar with candidates)
Our science based approach to recruitment will ensure you get not only the best candidate, but ensure the best candidate stays with your company. We are so confident in this new approach our retained clients will receive up to a 12 month guarantee on the candidates we place or we will replace them for free.
Laboratoires Théa , one of the leading independent European pharmaceutical groups in ophthalmology, have acquired seven branded ophthalmic products from Akorn, Inc including: Zioptan, AcellFX, Betimol, Cosopt, Cosopt PF, AzaSite and Akten. This move expands Théa’s presence into the US eye care industry.
“We are thrilled to expand our presence in the U.S. eye care community with a portfolio of products that are widely recognized and frequently used because they make a difference in patients’ lives,” said Susan Benton, Théa’s General Manager, Head of U.S. “As we introduce additional product lines and bring new innovations to market through our dedicated research and development programs, we are looking forward to engaging with stakeholders to expand our leadership presence on a global scale.”
Théa hope to bring innovative products for the US market in areas which are currently unmet. It is expected that they will file its first New Drug Application with the FDA in the first quarter of 2022 for a version of the glaucoma treatment latanoprost.
In the last quarter of 2022, Théa are planning to launch a new line of branded OTC evidenced-based dry-eye drops and eyelid hygiene products through Similasan Corporation; the leading global maker of eye drops.
James Pickering is our Managing Director and an eye care recruitment expert who has developed an extensive client base and candidate network. He regularly writes articles about industry developments and has received numerous recommendations from industry leaders. You can also connect with James on LinkedIn to stay up to date on the latest eye care news.